Evidence map›Paper›PMID 35655239›Full record

ArticleTrials2022

Value and engagement: what can clinical trials learn from techniques used in not-for-profit marketing?

E J Mitchell, K Sprange, S Treweek, E Nixon

Abstract readLetter
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

E J MitchellNottingham Clinical Trials Unit, Applied Health Research Building, University Park, University of Nottingham, Nottingham, NG7 2RD, UK. eleanor.mitchell@nottingham.ac.uk.ORCID http://orcid.org/0000-0002-6998-4533
K SprangeNottingham Clinical Trials Unit, Applied Health Research Building, University Park, University of Nottingham, Nottingham, NG7 2RD, UK.
S TreweekHealth Services Research Unit, Health Sciences Building, University of Aberdeen, Aberdeen, AB25 2ZD, UK.
E NixonNottingham University Business School, Jubilee Campus, University of Nottingham, Nottingham, NG8 1BB, UK.

Funding

Chief Scientist Office HSRU1
6 · The paper itself

Abstract

Marketing is a core business function in commercial companies but is also frequently used by not-for-profit organisations. Marketing focuses on understanding what people value to make choices about engaging with a product or service: a concept also key to understanding why people may choose to engage with a clinical trial. Understanding the needs and values of stakeholders, whether they are participants, staff at recruiting sites or policy-makers, is critical for a clinical trial to be a success. As many trials fail to recruit and retain participants, perhaps it is time for us to consider approaches from other disciplines. Though clinical trial teams may consider evidence- and non-evidence-based recruitment and retention strategies, this is rarely done in a systematic, streamlined way and is often in response to challenges once the trial has started. In this short commentary, we argue the need for a formal marketing approach to be applied to clinical trials, from the outset, as a potential prevention to recruitment and retention problems.

Indexed as

Administrative PersonnelMarketingHumansPatient SelectionMarketingRandomised trialsRecruitmentRetentionValue

Identifiers

PMID35655239
PMCPMC9164393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.